Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New P2Y12 antagonists.

Current opinion in hematology - 1 Sept 2009

Michelson Alan D

Abstract excerpt

PURPOSE OF REVIEW: The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists. This article reviews the current status of clopidogrel and these new P2Y12 antagonists. RECENT FINDINGS: A poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Fibrinolytic Agents
Share to Platelet Function Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Receptors, Purinergic P2Y12

Share to Ticlopidine

Share to Treatment Outcome

Source

Identifiers

PMID: 19550317
DOI: 10.1097/MOH.0b013e32832ea2f2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New P2Y12 antagonists.PMID 19550317Read ↗

Pharmacogenetics of P2Y 12 receptor inhibitorsSemantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.Semantic proximity Read ↗

Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet DrugsSemantic proximity Read ↗

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.Semantic proximity Read ↗

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?Semantic proximity Read ↗

Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.Semantic proximity Read ↗

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.Semantic proximity Read ↗

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.